实时荧光PCR联合检测非小细胞肺癌间变性淋巴瘤激酶与c-ros原癌基因1受体酪氨酸激酶的临床价值
研究采用基于荧光PCR的ALK与ROS1融合基因联合检测试剂盒,对302例非小细胞肺癌标本同时检测两种融合基因,并用Sanger测序验证。实时荧光PCR与Sanger测序的阳性、阴性及总符合率均为100%。作者认为该方法可同时检测微量ALK与ROS1融合基因、节省时间并避免重复取样,值得推荐为快速可靠的检测技术。
要点
- 302例非小细胞肺癌标本均成功完成荧光PCR检测(302/302)。
- ALK融合基因检出12例(4.0%),ROS1融合基因检出12例(4.0%),总检出率为7.9%(24/302)。
- 实时荧光PCR与Sanger测序的阳性、阴性及总符合率均为100%。
核心结论
- Sanger测序结果证明实时荧光PCR检测非小细胞肺癌组织ALK与ROS1融合基因同样有效。
- 实时荧光PCR可同时检测微量样本中的ALK与ROS1融合基因,节省时间并避免重复取样。
- 作者认为该技术值得推荐为快速可靠的检测技术。
研究设计与样本
- 采用基于荧光PCR的ALK融合基因与ROS1融合基因联合检测试剂盒,对302例非小细胞肺癌标本同时检测两种融合基因。
- 检测结果通过Sanger测序验证,并分析两种检测方法的一致性。
主要发现
- 302例非小细胞肺癌标本均通过荧光PCR成功分析(302/302)。
- 检出ALK融合基因12例(4.0%),包括ALK-M1 3例、ALK-M2 3例、ALK-M3 3例、ALK-M4 1例、ALK-M6 2例。
- 检出ROS1融合基因12例(4.0%),包括ROS1-M7 1例、ROS1-M8 8例、ROS1-M12 1例、ROS1-M14 1例、ROS1-M3与ROS1-M8双阳性1例。
- ALK与ROS1融合基因总检出率为7.9%(24/302),278例为ALK与ROS1融合基因阴性。
- Sanger DNA测序的成功检测率亦为100%,实时荧光PCR与Sanger DNA测序的阳性、阴性及总符合率均为100%。
临床怎么用
- 作者认为实时荧光PCR检测非小细胞肺癌组织ALK与ROS1融合基因同样有效,可同时检测微量样本中的两种融合基因,节省时间并避免重复取样。
- 作者认为该技术值得推荐为快速可靠的检测技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical application value of combined detection of ALK fusion gene and c-ros oncogene 1 receptor tyrosine kinase (ROS1) fusion gene in non-small cell lung cancer (NSCLC) using real-time fluorescent PCR. Methods: A kit for combined detection of ALK fusion gene and ROS1 fusion gene based on fluorescent PCR was used to simultaneously detect the two fusion genes in 302 cases of NSCLC specimens. The results were validated through Sanger sequencing. The consistency of the two detection methods was analyzed. Results: All 302 cases of NSCLC specimens were successfully analyzed through fluorescent PCR (302/302). 12 cases (4.0%) were found to contain ALK fusion gene, including 3 cases with ALK-M1, 3 with ALK-M2, 3 with ALK-M3, 1 with ALK-M4, and 2 with ALK-M6 fusion gene.12 cases (4.0%) were found to contain ROS1 fusion gene, including 1 case with ROS1-M7, 8 cases with ROS1-M8, 1 case with ROS1-M12, 1 case with ROS1-M14, and 1 case with double-positive ROS1-M3 and ROS1-M8 fusion genes. The total detection rate of ALK fusion gene and ROS1 fusion gene was 7.9% (24/302) and 278 cases showed to be negative for ALK fusion gene and ROS1 fusion gene. The successful detection rates for Sanger DNA sequencing were also 100%. The positive, negative and total coincidence rates obtained by real-time fluorescent PCR and by Sanger DNA sequencing were all 100%. Conclusions: The results of Sanger DNA sequencing demonstrate that the real-time fluorescent PCR assay is equally effective in detecting ALK and ROS1 fusion genes in NSCLC tissues. Furthermore, real-time fluorescent PCR assay can be used to detect trace ALK and ROS1 fusion gene simultaneously in tiny samples, and can save time and avoid repeated sampling. It is worthy of recommendation as a rapid and reliable detection technique.
引用
- Bai DY, Zhang HP, Zhong S, et al. [Clinical utility of real-time fluorescent PCR for combined detection of anaplastic lymphoma kinase and c-ros oncogene 1 receptor tyrosine kinase in non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998465. doi:10.3760/cma.j.issn.0253-3766.2016.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。